Clinical Trials on Liver Percutaneous Biopsy or Ablation in Sweden

Total 26 results

Kristina Gemzell Danielsson
Karolinska Institutet; The University of Hong Kong

Terminated

Randomized Study of Letrozole and Trilostane for Medical Abortion

Medical Abortion, Complete or Unspecified, Without Complication

Sweden
AstraZeneca

Completed

Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel

Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout

Sweden
Karolinska University Hospital
Karolinska Institutet

Completed

Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts

Benign Neoplasm of Liver and/or Biliary Ducts | Neoplasm of Uncertain Behavior of Biliary System | Benign Neoplasms of the Pancreas | Neoplasms of the Pancreas

Sweden
Alnylam Pharmaceuticals

Completed

A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

Porphyria, Acute Intermittent | Acute Intermittent Porphyria (AIP) | Acute Hepatic Porphyria (AHP) | Acute Porphyria

Sweden
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Completed

Study of DCR-A1AT in Healthy Adult Volunteers

Alpha 1-Antitrypsin Deficiency

New Zealand, Sweden
Arrowhead Pharmaceuticals

Withdrawn

Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

Alpha-1 Antitrypsin Deficiency

Ireland, Canada, Italy, Sweden
Karolinska University Hospital
Karolinska Institutet

Withdrawn

Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively

Hepatitis B | Hepatitis A | Tuberculosis | Cystic Fibrosis

Sweden
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Alnylam Pharmaceuticals

Completed

A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Acute Intermittent Porphyria

United States, United Kingdom, Sweden
Alnylam Pharmaceuticals

Completed

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Acute Intermittent Porphyria

United States, United Kingdom, Sweden
Kamada, Ltd.
Syneos Health

Recruiting

Evaluate Efficacy and Safety of "Kamada-AAT for Inhalation" in Patients With AATD (InnovAATe)

Alpha 1-Antitrypsin Deficiency

United Kingdom, Sweden, Ireland, Netherlands, Belgium, Finland
Kamada, Ltd.

Completed

International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema

Emphysema

United Kingdom, Canada, Denmark, Germany, Ireland, Netherlands, Sweden
National Cancer Institute (NCI)
Multicenter Hemophilia Cohort Study

Completed

The Second Multicenter Hemophilia Cohort Study

Hepatocellular Carcinoma | Non-Hodgkin Lymphoma | Liver Decompensation

United States, Germany, Italy, Brazil, Canada, France, Greece, Sweden
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Active, not recruiting

A Study of Belcesiran in Patients With AATLD (ESTRELLA)

Alpha 1-Antitrypsin Deficiency

United Kingdom, United States, Ireland, Belgium, New Zealand, Spain, Netherlands, Portugal, Canada, Australia, France, Austria, Germany, Sweden
Mereo BioPharma
Syneos Health

Completed

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. (ASTRAEUS)

Emphysema | Alpha 1-Antitrypsin Deficiency | COPD

United Kingdom, Belgium, United States, Denmark, Canada, Sweden, Poland, Spain
Alnylam Pharmaceuticals

Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE)

Acute Hepatic Porphyria

Belgium, France, Germany, United Kingdom, United States, Italy, Switzerland, Sweden
Mitsubishi Tanabe Pharma America Inc.

Active, not recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

EPP | XLP

United States, Germany, Japan, Spain, Italy, Sweden, Australia, Canada, Norway, United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Ascelia Pharma AB

Completed

Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function (SPARKLE)

Severe Renal Impairment | Known or Suspected Focal Liver Lesions

United States, Italy, Germany, Poland, Russian Federation, Sweden, Turkey, Argentina, Colombia, Mexico
CSL Behring

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Emphysema | Alpha 1-proteinase Inhibitor Deficiency

Australia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Alpha1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland, Sweden, United Kingdom
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
Grifols Therapeutics LLC

Enrolling by invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (SPARTA-OLE)

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

United States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France
Grifols Therapeutics LLC

Active, not recruiting

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)

Pulmonary Emphysema in Alpha-1 PI Deficiency

United States, Australia, Denmark, New Zealand, Estonia, Poland, Russian Federation, Sweden, Brazil, Canada, France, Finland
Alnylam Pharmaceuticals

Completed

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

Acute Hepatic Porphyria | Acute Intermittent Porphyria | Porphyria, Acute Intermittent | Acute Porphyria | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP)

United States, Spain, United Kingdom, Korea, Republic of, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Sweden, Taiwan

Clinical Trials on Liver Percutaneous Biopsy or Ablation in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations